CLOTRIMAZOLE TROCHE(clotrimazole lozenges) | Clotrimazole Troche

22:20 EDT 1st August 2015 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

FOR TOPICAL ORAL ADMINISTRATION

Each Clotrimazole Troche (clotrimazole lozenges) contains 10 mg clotrimazole [1-(o-chloro-α,α-diphenylbenzyl) imidazole], a synthetic antifungal agent, for topical use in the mouth.

Structural Formula:

The troche dosage form is a large, slowly dissolving tablet (lozenge) containing 10 mg of clotrimazole dispersed in croscarmellose sodium, dextrates, magnesium stearate, microcrystalline cellulose, and povidone.

IMAGE 0c5d3ee8-4f70-4492-bf3c-09e0aef1de44-01.jpg

Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal in vitro against Candida albicans and other species of the genus Candida at higher concentrations. No single-step or multiple-step resistance to clotrimazole has developed during successive passages of Candida albicans in the laboratory; however, individual organism tolerance has been observed during successive passages in the laboratory. Such in vitro tolerance has resolved once the organism has been removed from the antifungal environment.

After oral administration of a 10 mg clotrimazole troche to healthy volunteers, concentrations sufficient to inhibit most species of Candida persist in saliva for up to three hours following the approximately 30 minutes needed for a troche to dissolve. The long term persistence of drug in saliva appears to be related to the slow release of clotrimazole from the oral mucosa to which the drug is apparently bound. Repetitive dosing at three hour intervals maintains salivary levels above the minimum inhibitory concentrations of most strains of Candida; however, the relationship between in vitro susceptibility of pathogenic fungi to clotrimazole and prophylaxis or cure of infections in humans has not been established.

In another study, the mean serum concentrations were 4.98 ± 3.7 and 3.23 ± 1.4 nanograms/mL of clotrimazole at 30 and 60 minutes, respectively, after administration as a troche.

Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment.

Clotrimazole Troches (clotrimazole lozenges) are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION.)

Clotrimazole Troches (clotrimazole lozenges) are contraindicated in patients who are hypersensitive to any of its components.

Clotrimazole Troches (clotrimazole lozenges) are not indicated for the treatment of systemic mycoses including systemic candidiasis.

Abnormal liver function tests have been reported in patients treated with clotrimazole troches; elevated SGOT levels were reported in about 15% of patients in the clinical trials. In most cases the elevations were minimal and it was often impossible to distinguish effects of clotrimazole from those of other therapy and the underlying disease (malignancy in most cases). Periodic assessment of hepatic function is advisable particularly in patients with pre-existing hepatic impairment.

Since patients must be instructed to allow each troche to dissolve slowly in the mouth in order to achieve maximum effect of the medication, they must be of such an age and physical and/or mental condition to comprehend such instructions.

An 18 month dosing study with clotrimazole in rats has not revealed any carcinogenic effect.

Pregnancy Category C: Clotrimazole has been shown to be embryotoxic in rats and mice when given in doses 100 times the adult human dose (in mg/kg), possibly secondary to maternal toxicity. The drug was not teratogenic in mice, rabbits, and rats when given in doses up to 200, 180, and 100 times the human dose.

Clotrimazole given orally to mice from nine weeks before mating through weaning at a dose 120 times the human dose was associated with impairment of mating, decreased number of viable young, and decreased survival to weaning. No effects were observed at 60 times the human dose. When the drug was given to rats during a similar time period at 50 times the human dose, there was a slight decrease in the number of pups per litter and decreased pup viability.

There are no adequate and well controlled studies in pregnant women. Clotrimazole troches should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Safety and effectiveness of clotrimazole in children below the age of 3 years have not been established; therefore, its use in such patients is not recommended.

The safety and efficacy of the prophylactic use of clotrimazole troches in children have not been established.

Clinical studies of clotrimazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

Abnormal liver function tests have been reported in patients treated with clotrimazole troches; elevated SGOT levels were reported in about 15% of patients in the clinical trials (See PRECAUTIONS).

Nausea, vomiting, unpleasant mouth sensations and pruritus have also been reported with the use of the troche.

No data available.

No data available.

Clotrimazole Troches (clotrimazole lozenges) are administered only as a lozenge that must be slowly dissolved in the mouth. The recommended dose is one troche five times a day for fourteen consecutive days. Only limited data are available on the safety and effectiveness of the clotrimazole troche after prolonged administration; therefore, therapy should be limited to short term use, if possible.

For prophylaxis to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation, the recommended dose is one troche three times daily for the duration of chemotherapy or until steroids are reduced to maintenance levels.

Clotrimazole Troches (clotrimazole lozenges) are white, flat face tablets that are plain on one side and embossed with “54 552” on the other side.

Clotrimazole Troche (clotrimazole lozenge), 10 mg

0054-4146-22: Bottles of 70

0054-4146-23: Bottles of 140

0054-8146-22: 7 x 10 Unit-Dose Tablets

Store below 86°F (30°C). Avoid freezing.

10001777/03 Revised October 2007

© RLI, 2007

0054-4146-22: Bottles of 70

Rx Only

Roxane Laboratories, Inc.

0054-4146-23: Bottles of 140

Rx Only

Roxane Laboratories, Inc.

0054-8146-22: 7 x 10 Unit-Dose Tablets

Rx Only

Roxane Laboratories, Inc.

IMAGE 0c5d3ee8-4f70-4492-bf3c-09e0aef1de44-02.jpgIMAGE 0c5d3ee8-4f70-4492-bf3c-09e0aef1de44-03.jpgIMAGE 0c5d3ee8-4f70-4492-bf3c-09e0aef1de44-04.jpg

Manufacturer

Roxane Laboratories, Inc

Active Ingredients

Source

Drugs and Medications [46 Associated Drugs and Medications listed on BioPortfolio]

Clotrimazole troche [Cardinal Health]

CLOTRIMAZOLE TROCHE(clotrimazole lozenges)

Clotrimazole troche(clotrimazole lozenges) [Roxane]

CLOTRIMAZOLE TROCHE(clotrimazole lozenges)

Mycelex (clotrimazole) troche for topical oral administration [Bayer Pharmaceuticals Corp]

MYCELEX (clotrimazole) TROCHE FOR TOPICAL ORAL ADMINISTRATION

Clotrimazole and betamethasone dipropionate cream usprx only [Actavis Mid Atlantic LLC]

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE CREAM USPRx Only

Clotrimazole and betamethasone dipropionate [E. FOUGERA & CO. A division of Nycomed US Inc.]

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE LOTION USP, 1%/0.05% (base)

Clinical Trials [8 Associated Clinical Trials listed on BioPortfolio]

Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes

OBJECTIVES: Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes.

Comparative Efficacy of Ovule vs Tablet

The study is focused to prove that the efficacy of a new Canesten formulation (ovule) is not inferior to the old Canesten formulation (tablet)

Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis

The study is focused to prove that the efficacy and safety of Clotrimazole vaginal tablet vs Fluconazole for the treatment of severe vulvovaginal candidiasis

Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments

This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metr...

Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation

Tacrolimus (Prograf) belongs to a class of medications known as the calcineurin inhibitors. It is a maintenance drug that is used to prevent rejection in kidney, liver, and heart transplan...

PubMed Articles [12 Associated PubMed Articles listed on BioPortfolio]

Comparison of topical anti- fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study.

To compare the efficacy of topical antifungal agents, Sertaconazole and Clotrimazole in Tinea corporis patients.

Nanomicellar Formulation of Clotrimazole Improves Its Antitumor Action toward Human Breast Cancer Cells.

Although demonstrated as a selective anticancer drug, the clinical use of clotrimazole (CTZ) is limited due to its low solubility in hydrophilic fluids. Thus, we prepared a water-soluble nanomicellar ...

Mixture effects between different azoles and β-naphthoflavone on the CYP1A biomarker in a fish cell line.

The cytochrome P450 1A (CYP1A) biomarker response was studied in the Poeciliopsis lucida hepatocellular carcinoma (PLHC-1) cell line, which represents a good model for studies on aryl hydrocarbon rece...

The Use of the LanthaScreen TR-FRET CAR Coactivator Assay in the Characterization of Constitutive Androstane Receptor (CAR) Inverse Agonists.

The constitutive androstane receptor (CAR) is a critical nuclear receptor in the gene regulation of xenobiotic and endobiotic metabolism. The LanthaScreenTM TR-FRET CAR coactivator assay provides a si...

Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells.

Imatinib mesylate (IM), a tyrosine kinase inhibitor, is used as targeted cancer therapy. However, mono-targeting by IM does not always achieve full tumor eradication and thus it is recommended to comb...


Advertisement
 

Relevant Topics

Nutrition
Latest News Clinical Trials Research Drugs Reports Corporate
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Drug Discovery
Latest News Clinical Trials Research Drugs Reports Corporate
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Advertisement
 

Drugs and Medication Quicklinks


Searches Linking to this Drug Record